Revised Guidelines for the Clinical Management of Lynch Syndrome (HNPCC): Recommendations by a Group of European Experts

Overview

Journal Gut

Specialty Gastroenterology

Date 2013 Feb 15

PMID 23408351

Citations 280

Authors

Hans F A Vasen

Ignacio Blanco

Katja Aktan-Collan

Jessica P Gopie

Angel Alonso

Stefan Aretz

Inge Bernstein

Lucio Bertario

John Burn

Gabriel Capella

Chrystelle Colas

Christoph Engel

Ian M Frayling

Maurizio Genuardi

Karl Heinimann

Frederik J Hes

Shirley V Hodgson

John A Karagiannis

Fiona Lalloo

Annika Lindblom

Jukka-Pekka Mecklin

Pal Moller

Torben Myrhoj

Fokko M Nagengast

Yann Parc

Maurizio Ponz de Leon

Laura Renkonen-Sinisalo

Julian R Sampson

Astrid Stormorken

Rolf H Sijmons

Sabine Tejpar

Huw J W Thomas

Nils Rahner

Juul T Wijnen

Heikki Juhani Jarvinen

Gabriela Moslein

Affiliations

Soon will be listed here.

Abstract

Lynch syndrome (LS) is characterised by the development of colorectal cancer, endometrial cancer and various other cancers, and is caused by a mutation in one of the mismatch repair genes: MLH1, MSH2, MSH6 or PMS2. In 2007, a group of European experts (the Mallorca group) published guidelines for the clinical management of LS. Since then substantial new information has become available necessitating an update of the guidelines. In 2011 and 2012 workshops were organised in Palma de Mallorca. A total of 35 specialists from 13 countries participated in the meetings. The first step was to formulate important clinical questions. Then a systematic literature search was performed using the Pubmed database and manual searches of relevant articles. During the workshops the outcome of the literature search was discussed in detail. The guidelines described in this paper may be helpful for the appropriate management of families with LS. Prospective controlled studies should be undertaken to improve further the care of these families.

Citing Articles

Risk factors, prevention and screening of colorectal cancer: A rising problem.

Tsukanov V, Vasyutin A, Tonkikh J World J Gastroenterol. 2025; 31(5):98629.

PMID: 39926213 PMC: 11718609. DOI: 10.3748/wjg.v31.i5.98629.

Lynch Syndrome-Impact of the Type of Deficient Mismatch Repair Gene Mutation on Diagnosis, Clinical Presentation, Surveillance and Therapeutic Approaches.

Grigorie T, Potlog G, Alexandrescu S Medicina (Kaunas). 2025; 61(1).

PMID: 39859102 PMC: 11766940. DOI: 10.3390/medicina61010120.

Evolving Strategies in the Management of Microsatellite Instability-High/Mismatch Repair Deficient Esophagogastric Adenocarcinoma.

Balmaceda N, Kim S Curr Oncol Rep. 2025; 27(2):81-94.

PMID: 39832053 DOI: 10.1007/s11912-024-01624-4.

Haplotype analysis detects MLH1 founder variant in Indian Lynch syndrome patient cohort.

Sheth H, Sadhwani J, Jain A, Thenral S, Ramprasad V, Bishop D Fam Cancer. 2024; 24(1):13.

PMID: 39702679 DOI: 10.1007/s10689-024-00436-6.

Significant difference in gut microbiota Bifidobacterium species but not Lactobacillus species in colorectal cancer patients in comparison with healthy volunteers using quantitative real-time PCR.

Esfandiari F, Bakhshi B, Shahbazi T, Derakhshan-Nezhad E, Bahroudi M, Minaeeian S PLoS One. 2024; 19(11):e0294053.

PMID: 39602380 PMC: 11602092. DOI: 10.1371/journal.pone.0294053.

References

Quehenberger F, Vasen H, van Houwelingen H . Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet. 2005; 42(6):491-6. PMC: 1736072. DOI: 10.1136/jmg.2004.024299. View

van der Post R, Kiemeney L, Ligtenberg M, Witjes J, Hulsbergen-van de Kaa C, Bodmer D . Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet. 2010; 47(7):464-70. PMC: 2991077. DOI: 10.1136/jmg.2010.076992. View

Aarnio M, Salovaara R, Aaltonen L, Mecklin J, Jarvinen H . Features of gastric cancer in hereditary non-polyposis colorectal cancer syndrome. Int J Cancer. 1997; 74(5):551-5. DOI: 10.1002/(sici)1097-0215(19971021)74:5<551::aid-ijc13>3.0.co;2-9. View

Buerki N, Gautier L, Kovac M, Marra G, Buser M, Mueller H . Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer. 2011; 51(1):83-91. DOI: 10.1002/gcc.20935. View

Hemstreet 3rd G, Yin S, Ma Z, Bonner R, Bi W, Rao J . Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst. 2001; 93(6):427-36. DOI: 10.1093/jnci/93.6.427. View

Nieminen T, Gylling A, Abdel-Rahman W, Nuorva K, Aarnio M, Renkonen-Sinisalo L . Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res. 2009; 15(18):5772-83. DOI: 10.1158/1078-0432.CCR-09-0506. View

Gerritzen L, Hoogerbrugge N, Oei A, Nagengast F, van Ham M, Massuger L . Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Fam Cancer. 2009; 8(4):391-7. PMC: 2771130. DOI: 10.1007/s10689-009-9252-x. View

Dunlop M, Tenesa A, Farrington S, Ballereau S, Brewster D, Koessler T . Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42,103 individuals. Gut. 2012; 62(6):871-81. PMC: 5105590. DOI: 10.1136/gutjnl-2011-300537. View

Vasen H, Abdirahman M, Brohet R, Langers A, Kleibeuker J, van Kouwen M . One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology. 2010; 138(7):2300-6. DOI: 10.1053/j.gastro.2010.02.053. View

10.

Burn J, Bishop D, Mecklin J, Macrae F, Moslein G, Olschwang S . Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008; 359(24):2567-78. DOI: 10.1056/NEJMoa0801297. View

11.

Ketabi Z, Bartuma K, Bernstein I, Malander S, Gronberg H, Bjorck E . Ovarian cancer linked to Lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol. 2011; 121(3):462-5. DOI: 10.1016/j.ygyno.2011.02.010. View

12.

Rothwell P, Fowkes F, Belch J, Ogawa H, Warlow C, Meade T . Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2010; 377(9759):31-41. DOI: 10.1016/S0140-6736(10)62110-1. View

13.

Leung Ki E, Chan F . Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice. Best Pract Res Clin Gastroenterol. 2012; 26(2):163-72. DOI: 10.1016/j.bpg.2012.01.006. View

14.

Shiloh S, Koehly L, Jenkins J, Martin J, Hadley D . Monitoring coping style moderates emotional reactions to genetic testing for hereditary nonpolyposis colorectal cancer: a longitudinal study. Psychooncology. 2008; 17(8):746-55. DOI: 10.1002/pon.1338. View

15.

Baglietto L, Lindor N, Dowty J, White D, Wagner A, Gomez Garcia E . Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2009; 102(3):193-201. PMC: 2815724. DOI: 10.1093/jnci/djp473. View

16.

Liljegren A, Lindgren G, Brandberg Y, Rotstein S, Nilsson B, Hatschek T . Individuals with an increased risk of colorectal cancer: perceived benefits and psychological aspects of surveillance by means of regular colonoscopies. J Clin Oncol. 2004; 22(9):1736-42. DOI: 10.1200/JCO.2004.04.138. View

17.

Vasen H, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I . Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007; 44(6):353-62. PMC: 2740877. DOI: 10.1136/jmg.2007.048991. View

18.

Petersen H, Esplen M, Ladelund S, Bernstein I, Sunde L, Carlsson C . Limited impact on self-concept in individuals with Lynch syndrome; results from a national cohort study. Fam Cancer. 2011; 10(4):633-9. DOI: 10.1007/s10689-011-9459-5. View

19.

Houlle S, Charbonnier F, Houivet E, Tinat J, Buisine M, Caron O . Evaluation of Lynch syndrome modifier genes in 748 MMR mutation carriers. Eur J Hum Genet. 2011; 19(8):887-92. PMC: 3172927. DOI: 10.1038/ejhg.2011.44. View

20.

Diergaarde B, Braam H, Vasen H, Nagengast F, van Muijen G, Kok F . Environmental factors and colorectal tumor risk in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol. 2007; 5(6):736-42. DOI: 10.1016/j.cgh.2007.02.019. View